Morphotek, Inc.

Morphotek announces contract manufacturing and development collaboration agreement with Baxter Healthcare Corporation

Morphotek announces contract manufacturing and development collaboration agreement with Baxter Healthcare Corporation

October 20, 2003

Exton, PA - October 20, 2003 - Morphotek Inc announced today that it has signed a Contract Manufacturing and Development Collaboration Agreement for use of its proprietary MORPHODOMA® technology for the development of high-titer cell lines for the manufacture of monoclonal antibody products and other biologics.

Flagship Ventures names former president of Wyeth Research, L. Patrick Gage, Venture Partner

Flagship Ventures names former president of Wyeth Research, L. Patrick Gage, Venture Partner

October 23, 2003

Pharmaceutical executive to focus on biopharmaceutical innovators

Selventa

Genstruct Appoints Sharan A. Pagano Vice President, Business Development & Alliances

Genstruct Appoints Sharan A. Pagano Vice President, Business Development & Alliances

October 29, 2003

Former Incyte, Proteome Executive Joins Mechanism Discovery Company

Wednesday October 29, 9:00 am ET CAMBRIDGE MA - Genstruct Inc., a biotechnology company that develops conceptual biological models to determine compound mechanisms of action and identify biomarkers for drug discovery and development, today announced the appointment of Sharan A. Pagano as Vice President, Business Development & Alliances.

AVEO Pharmaceuticals, Inc.

GenPath Pharmaceuticals and Merck enter into potential $100 million deal for the discovery of novel cancer drugs

GenPath Pharmaceuticals and Merck enter into potential $100 million deal for the discovery of novel cancer drugs

November 17, 2003

CAMBRIDGE, Mass. - November 17, 2003 - GenPath Pharmaceuticals, Inc., a drug discovery and development company focused on the treatment of cancer and other diseases, announced today that it has entered into a multi-year collaborative agreement with Merck & Co., Inc. (NYSE: MRK). Under the agreement, GenPath will use its proprietary cancer models to identify essential tumor maintenance genes which maybe suitable targets for the development of small molecule oncology agents. GenPath will also use its inducible, spontaneous tumor models to guide candidate drug selection and optimization.

Morphotek, Inc.

Morphotek announces issuance of broad patent covering the generation of optimized yeast strains for biotherapeutic and biological product discovery, development, and manufacturing

Morphotek announces issuance of broad patent covering the generation of optimized yeast strains for biotherapeutic and biological product discovery, development, and manufacturing

December 15, 2003

Exton, PA, December 15, 2003 -- Morphotek Inc. announced today that the United States Patent and Trademark Office has issued it U.S. Patent 6,656,736 covering the generation of novel, genetically evolved yeast strains for use in biotherapeutic and biological product discovery, development, and manufacturing.

Affinnova, Inc.

Aéropostale Selects Affinnova's IDEA™ Technology To Evolve Winning Product Designs and Merchandising Mix With Direct Consumer Insight

Aéropostale Selects Affinnova's IDEA™ Technology To Evolve Winning Product Designs and Merchandising Mix With Direct Consumer Insight

December 15, 2003

First apparel retailer joins growing number of leading consumer products companies using Affinnova's IDEA™ technology to optimize the product development and marketing cycle

Mascoma Corporation

Mascoma Acquires SunOpta BioProcess Inc.

Mascoma Acquires SunOpta BioProcess Inc.

September 1, 2010

Creates global biofuels leader and industry’s first comprehensive capability for low-cost cellulosic biofuels

CGI Pharmaceuticals, Inc.

Gilead Sciences to Acquire CGI Pharmaceuticals for up to $120 Million

Gilead Sciences to Acquire CGI Pharmaceuticals for up to $120 Million

June 25, 2010

Deal to Broaden Gilead's Research Expertise into Kinase Biology and Chemistry

Ensemble Therapeutics Corporation

Ensemble Therapeutics Presents Data at American Chemical Society National Meeting

Ensemble Therapeutics Presents Data at American Chemical Society National Meeting

August 24, 2010

Progress with Macrocyclic-Based Drug Discovery Platform Highlighted

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Therapeutics announced today the presentation of data on its macrocyclic-based drug discovery platform at the American Chemical Society (ACS) National Meeting August 22-26, in Boston at the Boston Convention and Exposition Center.

Poster Presentations:

Flagship's David Berry Quoted in article in Technology Review: Death Knell for Some Clean Tech Companies

Flagship's David Berry Quoted in article in Technology Review: Death Knell for Some Clean Tech Companies

August 18, 2010

Partner David Berry, associated with several of Flagship's companies in the Sustainability sector. He was recently interviewed for a TR article on the potentials for a carbon cap-and-trade system in the US.